Bisoprolol is a second-generation, highly selective beta-1 adrenergic receptor antagonist with various beneficial effects in patients with heart failure. Interindividual variability in response to bisoprolol is known, and finding the optimal dose for individual patients with heart failure is still challenging. This pilot study included patients treated with bisoprolol for chronic heart failure with reduced ejection fraction. Between November 2022 and November 2023, one to six blood samples were collected from these patients to determine the trough serum concentration of bisoprolol. At the same time, the values of selected clinical variables were recorded. Bisoprolol concentrations ranged from 1.1 to 65.0 μg/L and correlated with both the daily dose and the dose per kilogram of body weight. However, wide variability in measured serum concentrations of bisoprolol was observed at the same daily dose and in apparent weight-adjusted clearance. Patients classified as NYHA III-IV received a 33% higher dose per kilogram of body weight than patients in NYHA I-II but achieved 165% higher serum concentrations of bisoprolol. An inverse correlation was found between diastolic blood pressure and dose per kilogram of body weight, and a positive correlation between N-terminal pro-B-type natriuretic peptide and both dose per kilogram of body weight and serum bisoprolol concentration. A wide variability in patients' serum concentrations of bisoprolol achieved after taking the same dose has been observed. A significantly higher concentration-to-dose ratio and a significantly lower weight-adjusted apparent clearance were demonstrated in patients with reduced cardiac function, reduced renal function, and taking the combination with amiodarone. These patients may be more prone to overdose with bisoprolol.

Department of Clinical Pharmacology Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Clinical Pharmacology Institute of Laboratory Medicine University Hospital Ostrava Ostrava Czech Republic

Department of Internal Medicine and Cardiology University Hospital Ostrava Ostrava Czech Republic

Department of Internal Medicine Faculty of Medicine University of Ostrava Ostrava Czech Republic

Zobrazit více v PubMed

Leopold G., Pabst J., Ungethum W., and Buhring K. U., “Basic Pharmacokinetics of Bisoprolol, a New Highly Beta 1‐Selective Adrenoceptor Antagonist,” Journal of Clinical Pharmacology 26, no. 8 (1986): 616–621, 10.1002/j.1552-4604.1986.tb02959.x. PubMed DOI

Fontana V., Turner R. M., Francis B., et al., “Chromosomal Region 11p14.1 Is Associated With Pharmacokinetics and Pharmacodynamics of Bisoprolol,” Pharmacogenomics and Personalized Medicine 15 (2022): 249–260, 10.2147/PGPM.S352719. PubMed DOI PMC

Investigators CI , “The Cardiac Insufficiency Bisoprolol Study II (CIBIS‐II): A Randomised Trial,” Lancet 353, no. 9146 (1999): 9–13. PubMed

Shin J. and Johnson J. A., “Pharmacogenetics of b‐Blockers,” Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 27 (2007): 874–887. PubMed PMC

Arita T., Suzuki S., Kato Y., et al., “Association Between Bisoprolol Plasma Concentration and Worsening of Heart Failure: (CVI ARO 6),” Drug Metabolism and Pharmacokinetics 35, no. 2 (2020): 228–237, 10.1016/j.dmpk.2020.01.002. PubMed DOI

Arita T., Suzuki S., Kato Y., et al., “Association Between Dose and Plasma Concentration of Bisoprolol in Patients With Heart Failure (CVI ARO 6),” International Heart Journal 61, no. 4 (2020): 748–754, 10.1536/ihj.20-052. PubMed DOI

Johnson E. L., Stowe Z. N., Ritchie J. C., et al., “Carbamazepine Clearance and Seizure Stability During Pregnancy,” Epilepsy & Behavior 33 (2014): 49–53, 10.1016/j.yebeh.2014.02.011. PubMed DOI PMC

Leor J., Levartowsky D., Sharon C., and Farfel Z., “Amiodarone and Beta‐Adrenergic Blockers: An Interaction With Metoprolol but Not With Atenolol,” American Heart Journal 116, no. 1 Pt 1 (1988): 206–207, 10.1016/0002-8703(88)90275-x. PubMed DOI

Werner D., Wuttke H., Fromm M. F., et al., “Effect of Amiodarone on the Plasma Levels of Metoprolol,” American Journal of Cardiology 94, no. 10 (2004): 1319–1321, 10.1016/j.amjcard.2004.07.125. PubMed DOI

Fukumoto K., Kobayashi T., Tachibana K., et al., “Effect of Amiodarone on the Serum Concentration/Dose Ratio of Metoprolol in Patients With Cardiac Arrhythmia,” Drug Metabolism and Pharmacokinetics 21, no. 6 (2006): 501–505, 10.2133/dmpk.21.501. PubMed DOI

Robert S., Pilon M. O., Oussaïd E., et al., “Impact of Amiodarone Use on Metoprolol Concentrations, α‐OH‐Metoprolol Concentrations, Metoprolol Dosing and Heart Rate: A Cross‐Sectional Study,” Pharmacology Research & Perspectives 11, no. 5 (2023): e01137, 10.1002/prp2.1137. PubMed DOI PMC

Taguchi M., Nozawa T., Igawa A., et al., “Pharmacokinetic Variability of Routinely Administered Bisoprolol in Middle‐Aged and Elderly Japanese Patients,” Biological & Pharmaceutical Bulletin 28, no. 5 (2005): 876–881, 10.1248/bpb.28.876. PubMed DOI

Okda S. M., El‐Bassiouny N. A., El Amrawy A. M., Salahuddin A., Elonsy S. M., and Kassem A. B., “Impact of CYP2D6*2A, CYP2D6*4 and CYP3A5*3 Genetic Polymorphisms on Bisoprolol Peak Concentration and Clinical Response in Acute Coronary Syndrome Patients,” British Journal of Clinical Pharmacology 90, no. 10 (2024): 2539–2553, 10.1111/bcp.16134. PubMed DOI

Trobec K. C., Grabnar I., Kos M. K., et al., “Bisoprolol Pharmacokinetics and Body Composition in Patients With Chronic Heart Failure: A Longitudinal Study,” European Journal of Clinical Pharmacology 72, no. 7 (2016): 813–822, 10.1007/s00228-016-2041-1. PubMed DOI

Kirch W., Rose I., Demers H. G., Leopold G., Pabst J., and Ohnhaus E. E., “Pharmacokinetics of Bisoprolol During Repeated Oral Administration to Healthy Volunteers and Patients With Kidney or Liver Disease,” Clinical Pharmacokinetics 13 (1987): 110–117. PubMed

Nikolic V. N., Jevtovic‐Stoimenov T., Velickovic‐Radovanović R., et al., “Population Pharmacokinetics of Bisoprolol in Patients With Chronic Heart Failure,” European Journal of Clinical Pharmacology 69 (2013): 859–865. PubMed

Momčilović S., Jovanović A., Radojković D., et al., “Population Pharmacokinetic Analysis of Bisoprolol in Type 2 Diabetic Patients With Hypertension,” European Journal of Clinical Pharmacology 76, no. 11 (2020): 1539–1546, 10.1007/s00228-020-02937-6. PubMed DOI

Rau T., Wuttke H., Michels L. M., et al., “Impact of the CYP2D6 Genotype on the Clinical Effects of Metoprolol: A Prospective Longitudinal Study,” Clinical Pharmacology and Therapeutics 85, no. 3 (2009): 269–272, 10.1038/clpt.2008.218. PubMed DOI

Pharmacogene Variation Consortium (PharmVar) , “CYP2D6,” accessed November 20, 2024, https://www.pharmvar.org/gene/CYP2D6.

Collett S., Massmann A., Petry N. J., et al., “Metoprolol and CYP2D6: A Retrospective Cohort Study Evaluating Genotype‐Based Outcomes,” Journal of Personalized Medicine 13, no. 3 (2023): 416, 10.3390/jpm13030416. PubMed DOI PMC

Blake C. M., Kharasch E. D., Schwab M., and Nagele P., “A Meta‐Analysis of CYP2D6 Metabolizer Phenotype and Metoprolol. Pharmacokinetics,” Clinical Pharmacology and Therapeutics 94 (2013): 394–399, 10.1038/clpt.2013.96. PubMed DOI PMC

Dean L. and Kane M., “Metoprolol Therapy and CYP2D6 Genotype,” April 4, 2017 [Updated September 19, 2024], in Medical Genetics Summaries, [Internet], ed. Pratt V. M., Scott S. A., Pirmohamed M., et al. (National Center for Biotechnology Information (US), 2012), accessed November 20, 2024, https://www.ncbi.nlm.nih.gov/books/NBK425389/.

Castaño‐Amores C., Díaz‐Villamarín X., Pérez‐Gutiérrez A. M., et al., “Pharmacogenetic Polymorphisms Affecting Bisoprolol Response,” Biomedicine & Pharmacotherapy 142 (2021): 112069, 10.1016/j.biopha.2021.112069. PubMed DOI

Shah R. R. and Smith R. L., “Addressing Phenoconversion: The Achilles' Heel of Personalized Medicine,” British Journal of Clinical Pharmacology 79 (2015): 222–240, 10.1111/bcp.12441. PubMed DOI PMC

Klomp S. D., Manson M. L., Guchelaar H. J., and Swen J. J., “Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review,” Journal of Clinical Medicine 9 (2020): 2890, 10.3390/jcm9092890. PubMed DOI PMC

Cicali E. J., Smith D. M., Duong B. Q., Kovar L. G., Cavallari L. H., and Johnson J. A., “A Scoping Review of the Evidence Behind CYP2D6 Inhibitor Classifications,” Clinical Pharmacology & Therapeutics 108 (2020): 116–125, 10.1002/cpt.1768. PubMed DOI PMC

Drug Development and Drug Interactions , “Table of Substrates, Inhibitors and Inducers,” accessed November 23, 2024, https://www.fda.gov/drugs/drug‐interactions‐labeling/drug‐development‐and‐drug‐interactions‐table‐substrates‐inhibitors‐and‐inducers.

Ohyama K., Nakajima M., Suzuki M., Shimada N., Yamazaki H., and Yokoi T., “Inhibitory Effects of Amiodarone and Its N‐Deethylated Metabolite on Human Cytochrome P450 Activities: Prediction of In Vivo Drug Interactions,” British Journal of Clinical Pharmacology 49, no. 3 (2000): 244–253, 10.1046/j.1365-2125.2000.00134.x. PubMed DOI PMC

Ohyama K., Nakajima M., Nakamura S., Shimada N., Yamazaki H., and Yokoi T., “A Significant Role of Human Cytochrome P450 2C8 in Amiodarone N‐Deethylation: An Approach to Predict the Contribution With Relative Activity Factor,” Drug Metabolism and Disposition 28, no. 11 (2000): 1303–1310. PubMed

Berger B., Bachmann F., Duthaler U., Krähenbühl S., and Haschke M., “Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug,” Frontiers in Pharmacology 9 (2018): 774, 10.3389/fphar.2018.00774. PubMed DOI PMC

Meloche M., Khazaka M., Kassem I., Barhdadi A., Dubé M.‐P., and de Denus S., “CYP2D6 Polymorphism and Its Impact on the Clinical Response to Metoprolol: A Systematic Review and Meta‐Analysis,” British Journal of Clinical Pharmacology 86, no. 6 (2020): 1015–1033, 10.1111/bcp.14247. PubMed DOI PMC

Zamir A., Hussain I., Ur Rehman A., et al., “Clinical Pharmacokinetics of Metoprolol: A Systematic Review,” Clinical Pharmacokinetics 61, no. 8 (2022): 1095–1114, 10.1007/s40262-022-01145-y. PubMed DOI

Kawabata M., Yokoyama Y., Sasaki T., et al., “Severe Iatrogenic Bradycardia Related to the Combined Use of Beta‐Blocking Agents and Sodium Channel Blockers,” Clinical Pharmacology 7 (2015): 29–36, 10.2147/cpaa.S77021. PubMed DOI PMC

Boutitie F., Boissel J. P., Connolly S. J., et al., “Amiodarone Interaction With β‐Blockers: Analysis of the Merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) Databases. The EMIAT and CAMIAT Investigators,” Circulation 99, no. 17 (1999): 2268–2275, 10.1161/01.cir.99.17.2268. PubMed DOI

Duricova J., Perinova I., Jurckova N., Kacirova I., and Grundmann M., “Clinically Important Interaction Between Metoprolol and Propafenone,” Canadian Family Physician 59, no. 4 (2013): 373–375. PubMed PMC

Kacirova I., Grundmann M., Kolek M., Vyskocilova‐Hrudikova E., Urinovska R., and Handlos P., “Lethal Suicide Attempt With a Mixed‐Drug Intoxication of Metoprolol and Propafenone – A First Pediatric Case Report,” Forensic Science International 278 (2017): e34–e40, 10.1016/j.forsciint.2017.06.025. PubMed DOI

Déniel A., Fedrizzi S., Lelong‐Boulouard V., Coquerel A., and Alexandre J., “Fatal Cardiac Arrest Associated With Concomitant Bisoprolol and Verapamil Overdose,” Journal of the American Geriatrics Society 64, no. 2 (2016): 451–452, 10.1111/jgs.13972. PubMed DOI

Hashiyada M., Usui K., Hayashizaki Y., et al., “Unexpectedly High Blood Concentration of Bisoprolol After an Incorrect Prescription: A Case Report,” Legal Medicine (Tokyo, Japan) 15, no. 2 (2013): 103–105, 10.1016/j.legalmed.2012.09.004. PubMed DOI

McAlister F. A., Wiebe N., Ezekowitz J. A., Leung A. A., and Armstrong P. W., “Meta‐Analysis: Beta‐Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure,” Annals of Internal Medicine 150, no. 11 (2009): 784–794, 10.7326/0003-4819-150-11-200906020-00006. PubMed DOI

M. T. de Oliveira, Jr. , Baptista R., Chavez‐Leal S. A., and Bonatto M. G., “Heart Failure Management With β‐Blockers: Can We Do Better?,” Current Medical Research and Opinion 40, no. sup1 (2024): 43–54, 10.1080/03007995.2024.2318002. PubMed DOI